233 related articles for article (PubMed ID: 37945286)
1. MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Charles-Schoeman C; Choy E; McInnes IB; Mysler E; Nash P; Yamaoka K; Lippe R; Khan N; Shmagel AK; Palac H; Suboticki J; Curtis JR
RMD Open; 2023 Nov; 9(4):. PubMed ID: 37945286
[TBL] [Abstract][Full Text] [Related]
2. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis.
Burmester GR; Cohen SB; Winthrop KL; Nash P; Irvine AD; Deodhar A; Mysler E; Tanaka Y; Liu J; Lacerda AP; Palac H; Shaw T; Mease PJ; Guttman-Yassky E
RMD Open; 2023 Feb; 9(1):. PubMed ID: 36754548
[TBL] [Abstract][Full Text] [Related]
3. Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme.
Fleischmann R; Curtis JR; Charles-Schoeman C; Mysler E; Yamaoka K; Richez C; Palac H; Dilley D; Liu J; Strengholt S; Burmester G
Ann Rheum Dis; 2023 Sep; 82(9):1130-1141. PubMed ID: 37308218
[TBL] [Abstract][Full Text] [Related]
4. Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials.
Burmester GR; Stigler J; Rubbert-Roth A; Tanaka Y; Azevedo VF; Coombs D; Lagunes I; Lippe R; Wung P; Gensler LS
Rheumatol Ther; 2024 Jun; 11(3):737-753. PubMed ID: 38683479
[TBL] [Abstract][Full Text] [Related]
5. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme.
Cohen SB; van Vollenhoven RF; Winthrop KL; Zerbini CAF; Tanaka Y; Bessette L; Zhang Y; Khan N; Hendrickson B; Enejosa JV; Burmester GR
Ann Rheum Dis; 2021 Mar; 80(3):304-311. PubMed ID: 33115760
[TBL] [Abstract][Full Text] [Related]
6. Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis.
Rubbert-Roth A; Kakehasi AM; Takeuchi T; Schmalzing M; Palac H; Coombs D; Liu J; Anyanwu SI; Lippe R; Curtis JR
Rheumatol Ther; 2024 Feb; 11(1):97-112. PubMed ID: 37982966
[TBL] [Abstract][Full Text] [Related]
7. Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials.
Burmester GR; Winthrop K; Blanco R; Nash P; Goupille P; Azevedo VF; Salvarani C; Rubbert-Roth A; Lesser E; Lippe R; Lertratanakul A; Mccaskill RM; Liu J; Ruderman EM
Rheumatol Ther; 2022 Apr; 9(2):521-539. PubMed ID: 34970731
[TBL] [Abstract][Full Text] [Related]
8. Safety of upadacitinib in Latin American patients with rheumatoid arthritis: an integrated safety analysis of the SELECT phase 3 clinical program.
Kakehasi AM; Radominski SC; Baravalle MD; Palazuelos FCI; Garcia-Garcia C; Arruda MS; Curi M; Liu J; Qiao M; Velez-Sanchez P; Vargas JI
Clin Rheumatol; 2023 May; 42(5):1249-1258. PubMed ID: 36715850
[TBL] [Abstract][Full Text] [Related]
9. Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials.
McInnes IB; Ostor AJK; Mease PJ; Tillett W; Baraliakos X; de Vlam K; Bessette L; Lippe R; Maniccia A; Feng D; Gao T; Zueger P; Saffore C; Kato K; Song IH; Deodhar A
RMD Open; 2022 Mar; 8(1):. PubMed ID: 35332058
[TBL] [Abstract][Full Text] [Related]
10. Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Rheumatoid Arthritis Treated with Long-Term Upadacitinib Therapy in Five Randomized Controlled Trials.
Bergman M; Buch MH; Tanaka Y; Citera G; Bahlas S; Wong E; Song Y; Zueger P; Ali M; Strand V
Rheumatol Ther; 2022 Dec; 9(6):1517-1529. PubMed ID: 36125701
[TBL] [Abstract][Full Text] [Related]
11. Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Husni ME; Deodhar A; Schwartzman S; Chakravarty SD; Hsia EC; Leu JH; Zhou Y; Lo KH; Kavanaugh A
Arthritis Res Ther; 2022 Mar; 24(1):73. PubMed ID: 35313978
[TBL] [Abstract][Full Text] [Related]
12. The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan.
Yamaoka K; Tanaka Y; Kameda H; Khan N; Sasaki N; Harigai M; Song Y; Zhang Y; Takeuchi T
Drug Saf; 2021 Jun; 44(6):711-722. PubMed ID: 34041702
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies.
Baraliakos X; Ranza R; Östör A; Ciccia F; Coates LC; Rednic S; Walsh JA; Douglas K; Gao T; Kato K; Song IH; Ganz F; Deodhar A
Arthritis Res Ther; 2023 Apr; 25(1):56. PubMed ID: 37038159
[TBL] [Abstract][Full Text] [Related]
14. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.
Mease P; Charles-Schoeman C; Cohen S; Fallon L; Woolcott J; Yun H; Kremer J; Greenberg J; Malley W; Onofrei A; Kanik KS; Graham D; Wang C; Connell C; Valdez H; Hauben M; Hung E; Madsen A; Jones TV; Curtis JR
Ann Rheum Dis; 2020 Nov; 79(11):1400-1413. PubMed ID: 32759265
[TBL] [Abstract][Full Text] [Related]
15. Comparative Persistence of Methotrexate and Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis.
George MD; Baker JF; Ogdie A
J Rheumatol; 2020 Jun; 47(6):826-834. PubMed ID: 31474599
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.
Ogdie A; de Vlam K; McInnes IB; Mease PJ; Baer P; Lukic T; Gruben D; Kwok K; Wang C; Hsu MA; Maniccia A
RMD Open; 2020 Feb; 6(1):. PubMed ID: 32396519
[TBL] [Abstract][Full Text] [Related]
17. Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis.
Nash P; Richette P; Gossec L; Marchesoni A; Ritchlin C; Kato K; McDearmon-Blondell EL; Lesser E; McCaskill R; Feng D; Anderson JK; Ruderman EM
Rheumatology (Oxford); 2022 Aug; 61(8):3257-3268. PubMed ID: 34864911
[TBL] [Abstract][Full Text] [Related]
18. Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study.
McInnes IB; Kato K; Magrey M; Merola JF; Kishimoto M; Pacheco-Tena C; Haaland D; Chen L; Duan Y; Zueger P; Liu J; Lippe R; Pangan AL; Behrens F
RMD Open; 2021 Oct; 7(3):. PubMed ID: 34663636
[TBL] [Abstract][Full Text] [Related]
19. Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 Trials.
Mease P; Kavanaugh A; Gladman D; FitzGerald O; Soriano ER; Nash P; Feng D; Lertratanakul A; Douglas K; Lippe R; Gossec L
Rheumatol Ther; 2022 Aug; 9(4):1181-1191. PubMed ID: 35606663
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy for pain management in inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis).
Ramiro S; Radner H; van der Heijde D; van Tubergen A; Buchbinder R; Aletaha D; Landewé RB
Cochrane Database Syst Rev; 2011 Oct; (10):CD008886. PubMed ID: 21975788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
